大塚アメリカ製薬株式会社
基本情報
- 所在地
- 508 Carnegie Center Dr, プリンストン, NJ 08540, アメリカ合衆国
- 社長
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 終了日
サイト
事業内容
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Avanir | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Verily |
関連図
沿革
ニュース
大塚製薬がFUS-ALSを対象とするウレフネルセンの第III相試験結果を発表
Otsuka's ulefnersen showed significant improvement in people with FUS-ALS, supporting its potential to modify disease progression. The drug was generally well tolerated, with mostly mild adverse events. The results will be discussed with regulatory authorities to explore the possibility of expedited approval.
GlomCon and Otsuka launch REIGNITE
GlomCon and Otsuka have launched the REIGNITE Study, a multi-year longitudinal registry that will enroll more than 6,000 patients with IgA nephropathy to evaluate treatment patterns and health outcomes. The resulting data will provide real-world evidence to help shape future disease management and patient care.
VOYXACT stabilizes kidney function in IgA nephropathy
The Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized eGFR slope of +0.3 mL/min/1.73 m²/year with VOYXACT versus −4.2 with placebo. VOYXACT is the first FDA-approved IgA nephropathy treatment to demonstrate stabilization of kidney function over two years, with a safety profile comparable to placebo. The results support selective APRIL inhibition as a disease-modifying approach targeting a key driver of IgA nephropathy.
VOYXACT stabilizes eGFR over two years
Otsuka will present Phase 3 VISIONARY data at GlomCon Hawaii 2026 showing that VOYXACT is the only APRIL inhibitor to achieve statistically significant eGFR stabilization over two years compared with placebo. The results support preservation of kidney function and reduced disease progression in IgA nephropathy, reinforcing selective APRIL inhibition as a safe, disease-modifying therapy targeting underlying drivers of the disease.
Otsuka reports positive results from Phase 3 VISIONARY study
VOYXACT (sibeprenlimab-szsi), the first APRIL inhibitor to demonstrate statistically significant eGFR stabilization over two years, showed marked reductions in the risk of kidney failure and improved kidney function in people with IgA nephropathy. The drug received U.S. FDA accelerated approval in November 2025 to reduce proteinuria in adults with the disease. These Phase 3 VISIONARY results complete the dataset and mark a milestone in Otsuka’s rolling submission of a supplemental Biologics License Application.